Revivo Therapeutics Receives NIH Funding

Revivo Therapeutics, Inc Receives a Project Award from the NIH                

"Advancement of Nomethiazole Therapeutics- The Development of a New Class of Procognitive and Disease Modifying Agents for Cognitive Decline" 

This NIH STTR grant, lead by Revivo Therapeutics, was funded jointly with Professor Greg Thatcher's Laboratory at the University of Chicago Illinois, and provides 2 years of additional funding to support basic and clinical science leading to the preclinical and clinical advancement of the Revivo's patent estate.  Dr. Doug Cowart, CEO of Revivo, stated that this is achievement will allow the company to move the lead Compound, RIV-5061 to IND stage, by enabling the company to complete development of the final dosage forms for use in the clinical studies.  Dr. Greg Thatcher, commented that this funding will further enable biochemical and histochemical measurements of effects of Nomethiazoles on inflammatory pathways that might be linked to neuropathology and neurodegeneration.  This funding is anticipated to further support further understanding of the mechanisms of action of this novel therapeutic class. 

Revivo Therapeutics Receives Founding Investments

Revivo Therapeutics has secured initial investments from private investors. According to Mr. Robert Bender, Chairman of the Board of Revivo Therapeutics, these investments are sufficient to advance the preclinical program substantially and position the company for support of the few IND-enabling studies to enable continuation of development. “According to Dr. Vince Kalish, SVP Chemistry, the company has selected its CMC providers and is advancing the program toward development of oral sustained release products.” Dr. Craig Hartman VP of Preclinical Development indicated that the “development plan leading to the re-submission of an IND for RIV-1061 is aggressive, but attainable within the scope of anticipated funding.”

Revivo Therapeutics announced that, following initial meetings with the North Carolina Biotechnology Council, it was applying for Company Inception Funding from NC Bio. NC Bio provides funding to enable development of promising new companies.

Revivo Therapeutics Announces Advisory Board Members Following Substantial Interest by Thought Leaders in R&D and Clinical Development

Dr. Doug Cowart, CEO and Dr. John Reardon, CSO of Revivo Therapeutics announced the company has completed the formation of its advisory board, which consists of leaders in both preclinical and clinical development of therapeutics directed at Alzheimer’s disease therapies.

Revivo Submits NIH Grant entitled “Advancement of Nomethiazole Therapeutics: The Development of a New Class of Procognitive and Disease Modifying Agents for Cognitive Decline”

Based on the existing science surrounding Nomethiazoles, Revivo Therapeutics completed an application for funding by the NIH in a SBIR grant proposal totaling over 3 million dollars. The Revivo Therapeutics team proposed a series of studies leading to the implementation of its Phase 1/2a studies of its reformulated product RIV-5061.

Revivo Therapeutics Organizes as a Delaware Corporation with North Carolina Headquarters

Following the agreement in principle for technology transfer agreement between the University of Illinois at Chicago and Queens University, Revivo announced its incorporation for the purpose of advancing the technology surrounding Nomethiazoles as a new class of therapeutic agents, targeting neurobehavioral function, cognitive enhancement and the reduction of disease progression.